Следене
Nikolay Vladimirov Conev
Nikolay Vladimirov Conev
Потвърден имейл адрес: mu-varna.bg
Заглавие
Позовавания
Позовавания
Година
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
15462019
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet Oncology 22 (1), 51-65, 2021
4392021
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, ...
ESMO open 7 (2), 100408, 2022
1392022
CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
Lancet 394 (10212), 1929-1939, 2019
1232019
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer
MP Petrova, MI Eneva, JI Arabadjiev, NV Conev, EG Dimitrova, ...
Bioscience trends 14 (1), 48-55, 2020
552020
Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients
NV Conev, IS Donev, AA Konsoulova-Kirova, TG Chervenkov, JK Kashlov, ...
Bioscience trends 9 (6), 393-401, 2015
462015
CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
Lancet Oncol 22 (1), 51-65, 2021
432021
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
MP Petrova, IS Donev, MA Radanova, MI Eneva, EG Dimitrova, ...
Clinical & Experimental Immunology 202 (3), 353-362, 2020
372020
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer
NV Conev, YK Kashlov, EG Dimitrova, YK Kashlov, MK Bogdanova, ...
Clinical and Investigative Medicine 42 (1), E31-E38, 2019
312019
PL02.11 Overall Survival with Durvalumab plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Sudy
L Paz-Ares, Y Chen, N Reinmuth, K Hotta, G Trukhin, J Statsenko, ...
2019 World Conference on Lung Cancer, 9, 2019
282019
LBA61 Durvalumab±tremelimumab+ platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
L Paz-Ares, Y Chen, N Reinmuth, K Hotta, D Trukhin, G Statsenko, ...
Annals of Oncology 32, S1338, 2021
272021
LBA86 Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
JW Goldman, MC Garassino, Y Chen, N Reinmuth, K Hotta, A Poltoratskiy, ...
Annals of Oncology 31, S1212-S1213, 2020
232020
Impact of brain metastases on treatment patterns and outcomes with first-line durvalumab plus platinum-etoposide in extensive-stage SCLC (CASPIAN): A brief report
Y Chen, L Paz-Ares, N Reinmuth, MC Garassino, G Statsenko, ...
JTO Clinical and Research Reports 3 (6), 100330, 2022
202022
Association between serum CK-18 levels and the degree of liver damage in fructose-induced metabolic syndrome
K Bratoeva, S Nikolova, A Merdzhanova, GS Stoyanov, E Dimitrova, ...
Metabolic syndrome and related disorders 16 (7), 350-357, 2018
202018
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
Y Chen, LG Paz-Ares, M Dvorkin, D Trukhin, N Reinmuth, MC Garassino, ...
Journal of Clinical Oncology 38 (15_suppl), 9068-9068, 2020
192020
Single nucleotide polymorphisms in microrna genes and colorectal cancer risk and prognosis
M Radanova, M Levkova, G Mihaylova, R Manev, M Maneva, R Hadgiev, ...
Biomedicines 10 (1), 156, 2022
142022
Circulating histones to detect and monitor the progression of cancer
DK Tsoneva, MN Ivanov, NV Conev, R Manev, DS Stoyanov, ...
International journal of molecular sciences 24 (2), 942, 2023
132023
Childhood obesity, renal injury and future disease risk
M Lateva, D Bliznakova, S Galcheva, Y Bocheva, M Neshkinska, ...
Scripta Scientifica Medica 49 (1), 38-46, 2017
12*2017
New circulating circular RNAs with diagnostic and prognostic potential in advanced colorectal cancer
M Radanova, G Mihaylova, O Tasinov, DP Ivanova, GS Stoyanov, ...
International Journal of Molecular Sciences 22 (24), 13283, 2021
112021
Rare case of ameloblastoma with pulmonary metastases
I Valkadinov, N Conev, D Dzhenkov, I Donev
Intractable & Rare Diseases Research 6 (3), 211-214, 2017
102017
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20